All News

Avidin’s laboratories, both Szeged headquarter and Budapest site are MSZ EN ISO 9001:2015 certified

Avidin together with partner Synaptogenex awarded with Market-leaded Research Development and Innovation Support 20.01.2020 Project title: Development, testing and production of active compounds and functional

Avidin demonstrates in Molecular Sciences Immunomodulatory Effect of Cisplatin explored with Single Cell Mass Cytometry 12.25.2019 Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of

Avidin publishes in Molecules the enantioselective synthesis of 8-hydroxyquinoline derivative, Q134 which is a hypoxic adaptation inducer 11.19.2019 Hypoxia is a common feature of neurodegenerative

Unique drug candidate being developed against Alzheimer’s disease reported by PharmaOnline (Hungarian) It has three mechanisms of action on important pathways of Alzheimer’s disease at

GenXPro Has Organized The Kick-Off Meeting For EUREKA (E!12655 MITOME) Innovation Collaboration With Partners Avidin And Steinbeis-Innovationszentrum Zellkulturtechnik (SIZ) In Frankfurt Monday 23. 09. /

Avidin participated in work on single cell mass cytometry of non-small cell lung cancer published in cells 09.16.2019 Single cell genomics and proteomics with the

AVIDIN synthetized Mannich curcuminoids, C142 and C150 showed potent anti-inflammatory properties, Special focus on …

Enantiomers of lead compounds for neurodegenerative diseases has been granted in the U.S.A. Avidin’s patent, entitled ‘Enantiomers of 8-Hydroxy Quinoline derivatives and the synthesis’ was